Phase II Study Of Single-Agent SU011248 In The Second-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma

Trial Profile

Phase II Study Of Single-Agent SU011248 In The Second-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2016

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 14 Nov 2016 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top